Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 1/2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 7Gastrointestinal 5Sarcoma 4Genitourinary 4Plasma cell 3Other hematologic neoplasm 3Gynecologic 3Thoracic 2Dermatologic 2Tumor-Agnostic 1Myeloid 1Head & Neck 1Classical hematology 1CNS 1Breast 1

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 141Lenalidomide 60Bortezomib 56Calcium Dobesilate 47Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10Cyclosporine 9pembrolizumab 8isatuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × X-Rays × Plasma cell × Clear all
NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Mayo Clinic

Phase 1/2 Active not recruiting
39 enrolled
Plasma cell

Multiple Myeloma

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Multiple Myeloma

NCT06572605 2025-09-19

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

City of Hope Medical Center

Phase 1/2 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡